| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-770 | |
| Phytochemical name or plant extracts | Ziyuglycoside II | |
| PMID | 24680927 | |
| Literature evidence | Our study indicated that ziyuglycoside II could effectively induce G2/M phase arrest and apoptosis in both cell lines. | |
| IUPAC name | (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponin | |
| Source of phytochemicals or plant Extracts | Sanguisorba officinalis | |
| Geographical availability | Alaska, Albania, Altay, Amur, Austria, Baltic States, Belarus, Belgium, British Columbia, Bulgaria, Buryatiya, California, Central European Rus, China North-Central, China South-Central, China Southeast, Chita, Czechoslovakia, East European Russia, France, Germany, Great Britain, Greece, Hungary, Iceland, Inner Mongolia, Iran, Ireland, Irkutsk, Italy, Japan, Kamchatka, Kazakhstan, Khabarovsk, Kirgizstan, Korea, Krasnoyarsk, Krym, Magadan, Maine, Manchuria, Michigan, Mongolia, Netherlands, North Caucasus, North European Russi, Northwest European R, Northwest Territorie, Norway, Nova Scotia, Oregon, Pennsylvania, Poland, Primorye, Qinghai, Romania, Sakhalin, South European Russi, Spain, Sweden, Switzerland, Taiwan, Tibet, Transcaucasus, Turkey, Tuva, Ukraine, Washington, West Siberia, Xinjiang, Yakutskiya, Yugoslavia, Yukon | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | Bax, Fas/FasL, Bcl-2, EMT | |
| Gene or Protein evidence | Further knockdown of JNK by siRNA could inhibit ziyuglycoside II-mediated apoptosis with attenuating the up-regulation of Bax and Fas/FasL as well as the down-regulation of Bcl-2. The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways. | |
| Target pathways | The extrinsic/Fas/FasL pathway as well as the intrinsic/mitochondrial pathway ROS/JNK pathway Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathway | |
| IC50 | 13.26 μM against MCF-7, 9.26 μM against MDA-MB-231 | |
| Potency | Our findings may significantly contribute to the understanding of the anti-proliferative effect of ziyuglycoside II, in particular to breast carcinoma and provide novel insights into the potential application of such compound in breast cancer therapy. | |
| Cell line/ mice model | MCF-7 and MDA-MB-231 | |
| Additional information | Ziyuglycoside II could effectively induce G2/M phase arrest and apoptosis in both cell lines. Cell cycle blocking was associated with the down-regulation of Cdc25C, Cdc2, cyclin A and cyclin B1 as well as the up-regulation of p21/WAF1, phospho-Cdc25C and phospho-Cdc2. Ziyuglycoside II treatment also induced reactive oxygen species (ROS) production and apoptosis by activating the extrinsic/Fas/FasL pathway as well as the intrinsic/mitochondrial pathway. | |
| PubChem ID | 71773126 | |
| Additional PMIDs | 24680927 31525383 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:741402-1 | |
| Safety | NA |